tradingkey.logo

Genfit SA

GNFT
查看详细走势图
4.850USD
0.000
收盘 12/26, 16:00美东报价延迟15分钟
242.51M总市值
--市盈率 TTM

Genfit SA

4.850
0.000
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

0.00%

5天

0.00%

1月

0.00%

6月

+26.30%

今年开始到现在

+30.55%

1年

+30.73%

查看详细走势图

TradingKey Genfit SA股票评分

单位: USD 更新时间: 2025-10-27

操作建议

当前估值合理,机构持股占比低,近一月多位分析师给出公司评级为强力买入。最高目标价max_target_price。目前股价在压力位和支撑位之间,可以做区间波段操作。

Genfit SA评分

相关信息

行业排名
269 / 501
全市场排名
480 / 4682
所属行业
生物技术与医疗研究

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

分析师目标

根据 7 位分析师
强力买入
评级
8.683
目标均价
+79.04%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Genfit SA亮点

亮点风险
Genfit SA is a France-based biopharmaceutical company focused on the discovery and development of therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, particularly due to a lack of approved treatments. The Company provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The Company leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.
业绩高增长
公司营业收入稳步增长,连续3年增长147.99%
业绩增长期
公司处于发展阶段,最新年度总收入62.29M美元
业绩转盈
公司业绩转盈,最新年度盈利美元
估值高估
公司最新PE估值145.37,处于3年历史高位
机构减仓
最新机构持股80.73K股,环比减少89.49%

Genfit SA新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Genfit SA简介

Genfit SA is a France-based biopharmaceutical company focused on the discovery and development of therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, particularly due to a lack of approved treatments. The Company provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The Company leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.
公司代码GNFT
公司Genfit SA
CEOPrigent (Pascal)
网址https://www.genfit.fr/

常见问题

Genfit SA(GNFT)的当前股价是多少?

Genfit SA(GNFT)的当前股价是 4.850。

Genfit SA的股票代码是什么?

Genfit SA的股票代码是GNFT。

Genfit SA股票的52周最高点是多少?

Genfit SA股票的52周最高点是4.929。

Genfit SA股票的52周最低点是多少?

Genfit SA股票的52周最低点是2.550。

Genfit SA的市值是多少?

Genfit SA的市值是242.51M。

Genfit SA的净利润是多少?

Genfit SA的净利润为1.51M。

现在Genfit SA(GNFT)的股票是买入、持有还是卖出?

根据分析师评级,Genfit SA(GNFT)的总体评级为--,目标价格为8.683。

Genfit SA(GNFT)股票的每股收益(EPS TTM)是多少

Genfit SA(GNFT)股票的每股收益(EPS TTM)是0.029。
KeyAI